| (Values in U.S. Thousands) | Mar, 2025 | Dec, 2024 | Sep, 2024 | Jun, 2024 | Mar, 2024 |
| Sales | 149,410 | 146,370 | 128,180 | 138,160 | 96,120 |
| Sales Growth | +2.08% | +14.19% | -7.22% | +43.74% | +33.57% |
| Net Income | 500 | -49,960 | -56,280 | -49,990 | 89,140 |
| Net Income Growth | +101.00% | +11.23% | -12.58% | -156.08% | +180.36% |
Blueprint Medicines Corp
(BPMC)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Blueprint Medicines Corporation is a biopharmaceutical company focused on developing the potentially transformational precision medicines to address patients with genomically defined cancers and rare diseases.
Fiscal Year End Date: 12/31